When Carlton Venable walked into the Casey Eye Institute in Portland in March 2020, surgeons injected three trillion molecular scissors directly into his retina. The scissors—CRISPR-Cas9 complexes loaded into an engineered virus—would find a specific spelling error in his DNA, make a single cut, and delete the broken section. If it worked, Venable would become the first person in history to have their genes edited inside their body. If it failed, he'd still be going blind from a disease with no other treatment options.

Four years later, we have the answer: it worked. And not just for Venable.

The Problem with CEP290

Leber Congenital Amaurosis type 10 shows up in the first years of life. Children with LCA10 lose their vision progressively, often ending in complete blindness. The culprit is a mutation in the CEP290 gene—specifically, a variant that inserts a chunk of genetic material where it doesn't belong, breaking the gene's instructions for building proteins essential to photoreceptor cells in the retina.

About 300 people in the United States have two copies of this particular mutation. That's the entire addressable patient population. It's a tiny number, but for those families, it's everything.

Traditional gene therapy couldn't touch this disease. The standard approach involves packaging a working copy of a gene into a virus that delivers it to the right cells. But CEP290 is simply too large to fit inside the adeno-associated viruses typically used for these deliveries. Researchers needed a different strategy: instead of replacing the gene, they would fix it in place.

Molecular GPS

CRISPR-Cas9 works like GPS-guided scissors. The guide RNA acts as the address, directing the Cas9 enzyme to one specific location among the three billion letters of the human genome. Once there, Cas9 makes a cut. The cell's own repair machinery then kicks in, stitching the DNA back together—hopefully with the defective section now removed.

For EDIT-101, the treatment developed by Editas Medicine, surgeons inject the CRISPR components directly into the space between the retina and the back of the eye. The injection requires precision. One eye receives the treatment; the other serves as an internal control. Each patient gets a single dose.

Dr. Eric Pierce, who led the trial at Massachusetts Eye and Ear, emphasized the elegant simplicity: "We're not adding anything new. We're just removing the piece that shouldn't be there."

What Happened in the BRILLIANCE Trial

Fourteen patients received EDIT-101 between March 2020 and late 2021. Twelve were adults between 17 and 63 years old. Two were children, ages 10 and 14. Researchers tested three different dose levels to find the optimal balance between efficacy and safety.

The results, published in The New England Journal of Medicine in May 2024, showed that 11 of the 14 patients—79%—experienced measurable vision improvements. Six people improved on at least two different outcome measures. Four gained clinically meaningful improvements in visual acuity, the standard eye chart test. Six showed better cone-mediated vision, which controls daytime and central vision.

The two patients who had two copies of the exact mutation the treatment targeted—the homozygous patients—both responded. That's a 100% response rate in the population most likely to benefit.

Pierce noted that some participants described life-changing shifts. People who couldn't read a single line on an eye chart could suddenly see the food on their plates. These aren't dramatic before-and-after stories of blindness to perfect vision, but they represent genuine functional improvements in daily life.

Perhaps more importantly: no serious adverse events occurred. No dose-limiting toxicities. The treatment appeared safe across all dose levels.

The Small Numbers Problem

Here's where the science meets economics. In November 2022, Editas Medicine announced it would pause enrollment and seek a partnership to continue development. The company pointed to the small patient population—those 300 people in the U.S. with the targetable mutation.

Developing a drug costs hundreds of millions of dollars. The FDA approval process demands extensive trials, long-term safety data, manufacturing infrastructure, and post-market surveillance. Even if EDIT-101 helped every eligible patient, the return on investment wouldn't cover development costs under traditional pharmaceutical business models.

This creates a brutal calculus. The trial proved CRISPR gene editing can work safely inside the human body. It showed that editing genes in the eye—an immune-privileged site that tolerates foreign material better than most organs—can improve vision in patients with inherited blindness. The science succeeded. But success in a clinical trial doesn't automatically translate to an approved therapy sitting in a hospital pharmacy.

Beyond LCA10

The pause in LCA10 development doesn't mean the work was wasted. BRILLIANCE established proof of concept for in vivo CRISPR editing. Every subsequent trial builds on this safety data and technical knowledge.

The eye offers unique advantages as a testing ground. It's relatively isolated from the rest of the body, limiting systemic exposure. It's small, requiring smaller doses. And researchers can directly observe the treated tissue through the pupil, monitoring for any concerning changes.

Other CRISPR trials for different diseases have already launched, using BRILLIANCE as a reference point for safety protocols. Some target the liver, where edited cells might correct metabolic disorders. Others aim at blood cells, treating sickle cell disease and beta-thalassemia.

The question isn't whether CRISPR will become a standard medical tool—it almost certainly will. The question is which diseases get treated first, and whether the economics of drug development can accommodate conditions that affect hundreds rather than hundreds of thousands.

When Rare Is Too Rare

Carlton Venable and the thirteen other BRILLIANCE participants live in a strange limbo. They received a treatment that worked. Their vision improved. But unless Editas finds a partner willing to shoulder the development costs, EDIT-101 may never reach the clinic as an approved therapy.

This might be the future of precision medicine: treatments tailored to specific genetic variants in specific genes, each applicable to a few hundred people. Scientific success without commercial viability. Proof that we can edit human genes safely and effectively, but uncertainty about whether we'll actually do it at scale.

Pierce maintains optimism: "This research demonstrates that CRISPR gene therapy for inherited vision loss is worth continued pursuit." Worth pursuing scientifically, certainly. Whether it's worth pursuing financially remains an open question—one that 300 families with LCA10 are waiting to have answered.